Posts by: David Melamed, PhD

David Melamed, PhD

David earned a PhD in Biological Sciences from Columbia University in New York, NY, where he studied how Drosophila ovarian adult stem cells respond to cell signaling pathway manipulations. This work helped to redefine the organizational principles underlying adult stem cell growth models. He is currently a Science Writer, as part of the BioNews Services writing team.

January 15, 2020

Dosing Begins in Study of Immune Checkpoint Inhibitor, Alone or in Combo, for Solid Tumors

News

A Phase 1 trial to treat advanced solid tumors has dosed its first patient with a combination of AGEN1181, a next generation CTLA-4 inhibitor, and the PD-1 inhibitor balstilimab — two ... Read more

January 9, 2020February 6, 2020

Dosing Begins in Phase 1 Trial of AGEN1223 Antibody for Advanced Solid Tumors

News

A Phase 1 clinical trial for people with advanced solid cancers has dosed its first participant with Agenus‘ investigational antibody, AGEN1223, a therapy designed to improve immune system efficiency in ... Read more

January 8, 2020

BioNTech’s CAR T-cell Therapy, Accompanying Vaccine Demonstrate High Anti-tumor Activity in Solid Tumors, Mouse Study Shows

News

Claudin 6, a cell surface protein involved in cell junction formation, may be a promising target for CAR T-cell therapies against solid tumors, according to a proof-of-concept study in mice. ... Read more